News
4hon MSN
Exclusive: Novo Nordisk cuts US obesity education team as layoffs begin, say sources, online posts
Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, ...
Novo Nordisk's shares rose by 5.4% on Thursday as investors turned more positive about the Danish drugmaker's prospects ...
Data from two studies show greater weight loss and comparable safety with a higher dose of semaglutide for those with and ...
A position paper argues that any systemic corticosteroid exposure in atopic dermatitis should trigger a transition to ...
Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling ...
The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom.
It is expected to create 650 jobs and is one of four U.S. manufacturing facilities the pharmaceutical giant plans to unveil ...
Eli Lilly (LLY) stock is in focus as its popular GLP-1 med Mounjaro hits main goals in a Phase 3 trial for children and ...
TipRanks on MSN
Eli Lilly’s Orforglipron Study: A Potential Game-Changer in Obesity and Diabetes Treatment
Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company recently completed a ...
Eli Lilly and Co. (NYSE: LLY) is one of the best beginner stocks to buy, according to analysts. On September 17, the company ...
MarketBeat on MSN
Eli Lilly's Oral GLP-1 Breakthrough Could Change Everything
Eli Lilly and Company (NYSE: LLY) has been one of the best-performing stocks outside of the AI-enhanced Magnificent 7 stocks ...
Drug maker Eli Lilly & Co. intends to build a $5 billion manufacturing site in Goochland County, the company announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results